Pharma & Healthcare
PEGylated Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 11, 24
- ID: 550064
- Pages: 127
- Figures: 209
- Views: 3
The global market for PEGylated Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PEGylated Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of PEGylated Drugs by region & country, by Type, and by Application.
The PEGylated Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PEGylated Drugs.
Market Segmentation
By Company
AstraZeneca
Bayer Healthcare
Biogen
BioMarin Pharmaceutical Inc
Coherus BioSciences
Enzon
Horizon Therapeutics
Leadiant Biosciences, Inc.
Merck
Mylan
Novo Nordisk
Pfizer
Roche
Sandoz
Servier Pharmaceuticals LLC
Takeda Pharmaceutical Company Limited
Segment by Type:
Macromolecular Drugs
Small Molecular Drugs
Nanoparticles
Segment by Application
Cancer
Hepatitis C
Leukemia
Severe Combined Immunodeficiency Disease
Rheumatoid Arthritis
Crohn Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of PEGylated Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of PEGylated Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of PEGylated Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PEGylated Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of PEGylated Drugs by region & country, by Type, and by Application.
The PEGylated Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PEGylated Drugs.
Market Segmentation
By Company
AstraZeneca
Bayer Healthcare
Biogen
BioMarin Pharmaceutical Inc
Coherus BioSciences
Enzon
Horizon Therapeutics
Leadiant Biosciences, Inc.
Merck
Mylan
Novo Nordisk
Pfizer
Roche
Sandoz
Servier Pharmaceuticals LLC
Takeda Pharmaceutical Company Limited
Segment by Type:
Macromolecular Drugs
Small Molecular Drugs
Nanoparticles
Segment by Application
Cancer
Hepatitis C
Leukemia
Severe Combined Immunodeficiency Disease
Rheumatoid Arthritis
Crohn Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of PEGylated Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of PEGylated Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of PEGylated Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 PEGylated Drugs Product Introduction
1.2 Global PEGylated Drugs Market Size Forecast
1.3 PEGylated Drugs Market Trends & Drivers
1.3.1 PEGylated Drugs Industry Trends
1.3.2 PEGylated Drugs Market Drivers & Opportunity
1.3.3 PEGylated Drugs Market Challenges
1.3.4 PEGylated Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global PEGylated Drugs Players Revenue Ranking (2023)
2.2 Global PEGylated Drugs Revenue by Company (2019-2024)
2.3 Key Companies PEGylated Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies PEGylated Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of PEGylated Drugs
2.6 PEGylated Drugs Market Competitive Analysis
2.6.1 PEGylated Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by PEGylated Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PEGylated Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Macromolecular Drugs
3.1.2 Small Molecular Drugs
3.1.3 Nanoparticles
3.2 Global PEGylated Drugs Sales Value by Type
3.2.1 Global PEGylated Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global PEGylated Drugs Sales Value, by Type (2019-2030)
3.2.3 Global PEGylated Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cancer
4.1.2 Hepatitis C
4.1.3 Leukemia
4.1.4 Severe Combined Immunodeficiency Disease
4.1.5 Rheumatoid Arthritis
4.1.6 Crohn Disease
4.1.7 Others
4.2 Global PEGylated Drugs Sales Value by Application
4.2.1 Global PEGylated Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global PEGylated Drugs Sales Value, by Application (2019-2030)
4.2.3 Global PEGylated Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global PEGylated Drugs Sales Value by Region
5.1.1 Global PEGylated Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global PEGylated Drugs Sales Value by Region (2019-2024)
5.1.3 Global PEGylated Drugs Sales Value by Region (2025-2030)
5.1.4 Global PEGylated Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America PEGylated Drugs Sales Value, 2019-2030
5.2.2 North America PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe PEGylated Drugs Sales Value, 2019-2030
5.3.2 Europe PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific PEGylated Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America PEGylated Drugs Sales Value, 2019-2030
5.5.2 South America PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa PEGylated Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions PEGylated Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions PEGylated Drugs Sales Value
6.3 United States
6.3.1 United States PEGylated Drugs Sales Value, 2019-2030
6.3.2 United States PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe PEGylated Drugs Sales Value, 2019-2030
6.4.2 Europe PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China PEGylated Drugs Sales Value, 2019-2030
6.5.2 China PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan PEGylated Drugs Sales Value, 2019-2030
6.6.2 Japan PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea PEGylated Drugs Sales Value, 2019-2030
6.7.2 South Korea PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia PEGylated Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India PEGylated Drugs Sales Value, 2019-2030
6.9.2 India PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India PEGylated Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Profile
7.1.2 AstraZeneca Main Business
7.1.3 AstraZeneca PEGylated Drugs Products, Services and Solutions
7.1.4 AstraZeneca PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 AstraZeneca Recent Developments
7.2 Bayer Healthcare
7.2.1 Bayer Healthcare Profile
7.2.2 Bayer Healthcare Main Business
7.2.3 Bayer Healthcare PEGylated Drugs Products, Services and Solutions
7.2.4 Bayer Healthcare PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Bayer Healthcare Recent Developments
7.3 Biogen
7.3.1 Biogen Profile
7.3.2 Biogen Main Business
7.3.3 Biogen PEGylated Drugs Products, Services and Solutions
7.3.4 Biogen PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 BioMarin Pharmaceutical Inc Recent Developments
7.4 BioMarin Pharmaceutical Inc
7.4.1 BioMarin Pharmaceutical Inc Profile
7.4.2 BioMarin Pharmaceutical Inc Main Business
7.4.3 BioMarin Pharmaceutical Inc PEGylated Drugs Products, Services and Solutions
7.4.4 BioMarin Pharmaceutical Inc PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 BioMarin Pharmaceutical Inc Recent Developments
7.5 Coherus BioSciences
7.5.1 Coherus BioSciences Profile
7.5.2 Coherus BioSciences Main Business
7.5.3 Coherus BioSciences PEGylated Drugs Products, Services and Solutions
7.5.4 Coherus BioSciences PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Coherus BioSciences Recent Developments
7.6 Enzon
7.6.1 Enzon Profile
7.6.2 Enzon Main Business
7.6.3 Enzon PEGylated Drugs Products, Services and Solutions
7.6.4 Enzon PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Enzon Recent Developments
7.7 Horizon Therapeutics
7.7.1 Horizon Therapeutics Profile
7.7.2 Horizon Therapeutics Main Business
7.7.3 Horizon Therapeutics PEGylated Drugs Products, Services and Solutions
7.7.4 Horizon Therapeutics PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 Horizon Therapeutics Recent Developments
7.8 Leadiant Biosciences, Inc.
7.8.1 Leadiant Biosciences, Inc. Profile
7.8.2 Leadiant Biosciences, Inc. Main Business
7.8.3 Leadiant Biosciences, Inc. PEGylated Drugs Products, Services and Solutions
7.8.4 Leadiant Biosciences, Inc. PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 Leadiant Biosciences, Inc. Recent Developments
7.9 Merck
7.9.1 Merck Profile
7.9.2 Merck Main Business
7.9.3 Merck PEGylated Drugs Products, Services and Solutions
7.9.4 Merck PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 Merck Recent Developments
7.10 Mylan
7.10.1 Mylan Profile
7.10.2 Mylan Main Business
7.10.3 Mylan PEGylated Drugs Products, Services and Solutions
7.10.4 Mylan PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Mylan Recent Developments
7.11 Novo Nordisk
7.11.1 Novo Nordisk Profile
7.11.2 Novo Nordisk Main Business
7.11.3 Novo Nordisk PEGylated Drugs Products, Services and Solutions
7.11.4 Novo Nordisk PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 Novo Nordisk Recent Developments
7.12 Pfizer
7.12.1 Pfizer Profile
7.12.2 Pfizer Main Business
7.12.3 Pfizer PEGylated Drugs Products, Services and Solutions
7.12.4 Pfizer PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.12.5 Pfizer Recent Developments
7.13 Roche
7.13.1 Roche Profile
7.13.2 Roche Main Business
7.13.3 Roche PEGylated Drugs Products, Services and Solutions
7.13.4 Roche PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.13.5 Roche Recent Developments
7.14 Sandoz
7.14.1 Sandoz Profile
7.14.2 Sandoz Main Business
7.14.3 Sandoz PEGylated Drugs Products, Services and Solutions
7.14.4 Sandoz PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.14.5 Sandoz Recent Developments
7.15 Servier Pharmaceuticals LLC
7.15.1 Servier Pharmaceuticals LLC Profile
7.15.2 Servier Pharmaceuticals LLC Main Business
7.15.3 Servier Pharmaceuticals LLC PEGylated Drugs Products, Services and Solutions
7.15.4 Servier Pharmaceuticals LLC PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.15.5 Servier Pharmaceuticals LLC Recent Developments
7.16 Takeda Pharmaceutical Company Limited
7.16.1 Takeda Pharmaceutical Company Limited Profile
7.16.2 Takeda Pharmaceutical Company Limited Main Business
7.16.3 Takeda Pharmaceutical Company Limited PEGylated Drugs Products, Services and Solutions
7.16.4 Takeda Pharmaceutical Company Limited PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.16.5 Takeda Pharmaceutical Company Limited Recent Developments
8 Industry Chain Analysis
8.1 PEGylated Drugs Industrial Chain
8.2 PEGylated Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 PEGylated Drugs Sales Model
8.5.2 Sales Channel
8.5.3 PEGylated Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 PEGylated Drugs Product Introduction
1.2 Global PEGylated Drugs Market Size Forecast
1.3 PEGylated Drugs Market Trends & Drivers
1.3.1 PEGylated Drugs Industry Trends
1.3.2 PEGylated Drugs Market Drivers & Opportunity
1.3.3 PEGylated Drugs Market Challenges
1.3.4 PEGylated Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global PEGylated Drugs Players Revenue Ranking (2023)
2.2 Global PEGylated Drugs Revenue by Company (2019-2024)
2.3 Key Companies PEGylated Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies PEGylated Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of PEGylated Drugs
2.6 PEGylated Drugs Market Competitive Analysis
2.6.1 PEGylated Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by PEGylated Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PEGylated Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Macromolecular Drugs
3.1.2 Small Molecular Drugs
3.1.3 Nanoparticles
3.2 Global PEGylated Drugs Sales Value by Type
3.2.1 Global PEGylated Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global PEGylated Drugs Sales Value, by Type (2019-2030)
3.2.3 Global PEGylated Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cancer
4.1.2 Hepatitis C
4.1.3 Leukemia
4.1.4 Severe Combined Immunodeficiency Disease
4.1.5 Rheumatoid Arthritis
4.1.6 Crohn Disease
4.1.7 Others
4.2 Global PEGylated Drugs Sales Value by Application
4.2.1 Global PEGylated Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global PEGylated Drugs Sales Value, by Application (2019-2030)
4.2.3 Global PEGylated Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global PEGylated Drugs Sales Value by Region
5.1.1 Global PEGylated Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global PEGylated Drugs Sales Value by Region (2019-2024)
5.1.3 Global PEGylated Drugs Sales Value by Region (2025-2030)
5.1.4 Global PEGylated Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America PEGylated Drugs Sales Value, 2019-2030
5.2.2 North America PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe PEGylated Drugs Sales Value, 2019-2030
5.3.2 Europe PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific PEGylated Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America PEGylated Drugs Sales Value, 2019-2030
5.5.2 South America PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa PEGylated Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions PEGylated Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions PEGylated Drugs Sales Value
6.3 United States
6.3.1 United States PEGylated Drugs Sales Value, 2019-2030
6.3.2 United States PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe PEGylated Drugs Sales Value, 2019-2030
6.4.2 Europe PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China PEGylated Drugs Sales Value, 2019-2030
6.5.2 China PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan PEGylated Drugs Sales Value, 2019-2030
6.6.2 Japan PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea PEGylated Drugs Sales Value, 2019-2030
6.7.2 South Korea PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia PEGylated Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia PEGylated Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India PEGylated Drugs Sales Value, 2019-2030
6.9.2 India PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India PEGylated Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Profile
7.1.2 AstraZeneca Main Business
7.1.3 AstraZeneca PEGylated Drugs Products, Services and Solutions
7.1.4 AstraZeneca PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 AstraZeneca Recent Developments
7.2 Bayer Healthcare
7.2.1 Bayer Healthcare Profile
7.2.2 Bayer Healthcare Main Business
7.2.3 Bayer Healthcare PEGylated Drugs Products, Services and Solutions
7.2.4 Bayer Healthcare PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Bayer Healthcare Recent Developments
7.3 Biogen
7.3.1 Biogen Profile
7.3.2 Biogen Main Business
7.3.3 Biogen PEGylated Drugs Products, Services and Solutions
7.3.4 Biogen PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 BioMarin Pharmaceutical Inc Recent Developments
7.4 BioMarin Pharmaceutical Inc
7.4.1 BioMarin Pharmaceutical Inc Profile
7.4.2 BioMarin Pharmaceutical Inc Main Business
7.4.3 BioMarin Pharmaceutical Inc PEGylated Drugs Products, Services and Solutions
7.4.4 BioMarin Pharmaceutical Inc PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 BioMarin Pharmaceutical Inc Recent Developments
7.5 Coherus BioSciences
7.5.1 Coherus BioSciences Profile
7.5.2 Coherus BioSciences Main Business
7.5.3 Coherus BioSciences PEGylated Drugs Products, Services and Solutions
7.5.4 Coherus BioSciences PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Coherus BioSciences Recent Developments
7.6 Enzon
7.6.1 Enzon Profile
7.6.2 Enzon Main Business
7.6.3 Enzon PEGylated Drugs Products, Services and Solutions
7.6.4 Enzon PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Enzon Recent Developments
7.7 Horizon Therapeutics
7.7.1 Horizon Therapeutics Profile
7.7.2 Horizon Therapeutics Main Business
7.7.3 Horizon Therapeutics PEGylated Drugs Products, Services and Solutions
7.7.4 Horizon Therapeutics PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 Horizon Therapeutics Recent Developments
7.8 Leadiant Biosciences, Inc.
7.8.1 Leadiant Biosciences, Inc. Profile
7.8.2 Leadiant Biosciences, Inc. Main Business
7.8.3 Leadiant Biosciences, Inc. PEGylated Drugs Products, Services and Solutions
7.8.4 Leadiant Biosciences, Inc. PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 Leadiant Biosciences, Inc. Recent Developments
7.9 Merck
7.9.1 Merck Profile
7.9.2 Merck Main Business
7.9.3 Merck PEGylated Drugs Products, Services and Solutions
7.9.4 Merck PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 Merck Recent Developments
7.10 Mylan
7.10.1 Mylan Profile
7.10.2 Mylan Main Business
7.10.3 Mylan PEGylated Drugs Products, Services and Solutions
7.10.4 Mylan PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Mylan Recent Developments
7.11 Novo Nordisk
7.11.1 Novo Nordisk Profile
7.11.2 Novo Nordisk Main Business
7.11.3 Novo Nordisk PEGylated Drugs Products, Services and Solutions
7.11.4 Novo Nordisk PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 Novo Nordisk Recent Developments
7.12 Pfizer
7.12.1 Pfizer Profile
7.12.2 Pfizer Main Business
7.12.3 Pfizer PEGylated Drugs Products, Services and Solutions
7.12.4 Pfizer PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.12.5 Pfizer Recent Developments
7.13 Roche
7.13.1 Roche Profile
7.13.2 Roche Main Business
7.13.3 Roche PEGylated Drugs Products, Services and Solutions
7.13.4 Roche PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.13.5 Roche Recent Developments
7.14 Sandoz
7.14.1 Sandoz Profile
7.14.2 Sandoz Main Business
7.14.3 Sandoz PEGylated Drugs Products, Services and Solutions
7.14.4 Sandoz PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.14.5 Sandoz Recent Developments
7.15 Servier Pharmaceuticals LLC
7.15.1 Servier Pharmaceuticals LLC Profile
7.15.2 Servier Pharmaceuticals LLC Main Business
7.15.3 Servier Pharmaceuticals LLC PEGylated Drugs Products, Services and Solutions
7.15.4 Servier Pharmaceuticals LLC PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.15.5 Servier Pharmaceuticals LLC Recent Developments
7.16 Takeda Pharmaceutical Company Limited
7.16.1 Takeda Pharmaceutical Company Limited Profile
7.16.2 Takeda Pharmaceutical Company Limited Main Business
7.16.3 Takeda Pharmaceutical Company Limited PEGylated Drugs Products, Services and Solutions
7.16.4 Takeda Pharmaceutical Company Limited PEGylated Drugs Revenue (US$ Million) & (2019-2024)
7.16.5 Takeda Pharmaceutical Company Limited Recent Developments
8 Industry Chain Analysis
8.1 PEGylated Drugs Industrial Chain
8.2 PEGylated Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 PEGylated Drugs Sales Model
8.5.2 Sales Channel
8.5.3 PEGylated Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. PEGylated Drugs Market Trends
Table 2. PEGylated Drugs Market Drivers & Opportunity
Table 3. PEGylated Drugs Market Challenges
Table 4. PEGylated Drugs Market Restraints
Table 5. Global PEGylated Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global PEGylated Drugs Revenue Market Share by Company (2019-2024)
Table 7. Key Companies PEGylated Drugs Manufacturing Base Distribution and Headquarters
Table 8. Key Companies PEGylated Drugs Product Type
Table 9. Key Companies Time to Begin Mass Production of PEGylated Drugs
Table 10. Global PEGylated Drugs Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PEGylated Drugs as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global PEGylated Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global PEGylated Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global PEGylated Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global PEGylated Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global PEGylated Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global PEGylated Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global PEGylated Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global PEGylated Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global PEGylated Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global PEGylated Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global PEGylated Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global PEGylated Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global PEGylated Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global PEGylated Drugs Sales Value by Region (2019-2024) & (%)
Table 27. Global PEGylated Drugs Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions PEGylated Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions PEGylated Drugs Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions PEGylated Drugs Sales Value, (2025-2030) & (US$ Million)
Table 31. AstraZeneca Basic Information List
Table 32. AstraZeneca Description and Business Overview
Table 33. AstraZeneca PEGylated Drugs Products, Services and Solutions
Table 34. Revenue (US$ Million) in PEGylated Drugs Business of AstraZeneca (2019-2024)
Table 35. AstraZeneca Recent Developments
Table 36. Bayer Healthcare Basic Information List
Table 37. Bayer Healthcare Description and Business Overview
Table 38. Bayer Healthcare PEGylated Drugs Products, Services and Solutions
Table 39. Revenue (US$ Million) in PEGylated Drugs Business of Bayer Healthcare (2019-2024)
Table 40. Bayer Healthcare Recent Developments
Table 41. Biogen Basic Information List
Table 42. Biogen Description and Business Overview
Table 43. Biogen PEGylated Drugs Products, Services and Solutions
Table 44. Revenue (US$ Million) in PEGylated Drugs Business of Biogen (2019-2024)
Table 45. Biogen Recent Developments
Table 46. BioMarin Pharmaceutical Inc Basic Information List
Table 47. BioMarin Pharmaceutical Inc Description and Business Overview
Table 48. BioMarin Pharmaceutical Inc PEGylated Drugs Products, Services and Solutions
Table 49. Revenue (US$ Million) in PEGylated Drugs Business of BioMarin Pharmaceutical Inc (2019-2024)
Table 50. BioMarin Pharmaceutical Inc Recent Developments
Table 51. Coherus BioSciences Basic Information List
Table 52. Coherus BioSciences Description and Business Overview
Table 53. Coherus BioSciences PEGylated Drugs Products, Services and Solutions
Table 54. Revenue (US$ Million) in PEGylated Drugs Business of Coherus BioSciences (2019-2024)
Table 55. Coherus BioSciences Recent Developments
Table 56. Enzon Basic Information List
Table 57. Enzon Description and Business Overview
Table 58. Enzon PEGylated Drugs Products, Services and Solutions
Table 59. Revenue (US$ Million) in PEGylated Drugs Business of Enzon (2019-2024)
Table 60. Enzon Recent Developments
Table 61. Horizon Therapeutics Basic Information List
Table 62. Horizon Therapeutics Description and Business Overview
Table 63. Horizon Therapeutics PEGylated Drugs Products, Services and Solutions
Table 64. Revenue (US$ Million) in PEGylated Drugs Business of Horizon Therapeutics (2019-2024)
Table 65. Horizon Therapeutics Recent Developments
Table 66. Leadiant Biosciences, Inc. Basic Information List
Table 67. Leadiant Biosciences, Inc. Description and Business Overview
Table 68. Leadiant Biosciences, Inc. PEGylated Drugs Products, Services and Solutions
Table 69. Revenue (US$ Million) in PEGylated Drugs Business of Leadiant Biosciences, Inc. (2019-2024)
Table 70. Leadiant Biosciences, Inc. Recent Developments
Table 71. Merck Basic Information List
Table 72. Merck Description and Business Overview
Table 73. Merck PEGylated Drugs Products, Services and Solutions
Table 74. Revenue (US$ Million) in PEGylated Drugs Business of Merck (2019-2024)
Table 75. Merck Recent Developments
Table 76. Mylan Basic Information List
Table 77. Mylan Description and Business Overview
Table 78. Mylan PEGylated Drugs Products, Services and Solutions
Table 79. Revenue (US$ Million) in PEGylated Drugs Business of Mylan (2019-2024)
Table 80. Mylan Recent Developments
Table 81. Novo Nordisk Basic Information List
Table 82. Novo Nordisk Description and Business Overview
Table 83. Novo Nordisk PEGylated Drugs Products, Services and Solutions
Table 84. Revenue (US$ Million) in PEGylated Drugs Business of Novo Nordisk (2019-2024)
Table 85. Novo Nordisk Recent Developments
Table 86. Pfizer Basic Information List
Table 87. Pfizer Description and Business Overview
Table 88. Pfizer PEGylated Drugs Products, Services and Solutions
Table 89. Revenue (US$ Million) in PEGylated Drugs Business of Pfizer (2019-2024)
Table 90. Pfizer Recent Developments
Table 91. Roche Basic Information List
Table 92. Roche Description and Business Overview
Table 93. Roche PEGylated Drugs Products, Services and Solutions
Table 94. Revenue (US$ Million) in PEGylated Drugs Business of Roche (2019-2024)
Table 95. Roche Recent Developments
Table 96. Sandoz Basic Information List
Table 97. Sandoz Description and Business Overview
Table 98. Sandoz PEGylated Drugs Products, Services and Solutions
Table 99. Revenue (US$ Million) in PEGylated Drugs Business of Sandoz (2019-2024)
Table 100. Sandoz Recent Developments
Table 101. Servier Pharmaceuticals LLC Basic Information List
Table 102. Servier Pharmaceuticals LLC Description and Business Overview
Table 103. Servier Pharmaceuticals LLC PEGylated Drugs Products, Services and Solutions
Table 104. Revenue (US$ Million) in PEGylated Drugs Business of Servier Pharmaceuticals LLC (2019-2024)
Table 105. Servier Pharmaceuticals LLC Recent Developments
Table 106. Takeda Pharmaceutical Company Limited Basic Information List
Table 107. Takeda Pharmaceutical Company Limited Description and Business Overview
Table 108. Takeda Pharmaceutical Company Limited PEGylated Drugs Products, Services and Solutions
Table 109. Revenue (US$ Million) in PEGylated Drugs Business of Takeda Pharmaceutical Company Limited (2019-2024)
Table 110. Takeda Pharmaceutical Company Limited Recent Developments
Table 111. Key Raw Materials Lists
Table 112. Raw Materials Key Suppliers Lists
Table 113. PEGylated Drugs Downstream Customers
Table 114. PEGylated Drugs Distributors List
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
Table 118. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. PEGylated Drugs Product Picture
Figure 2. Global PEGylated Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. PEGylated Drugs Report Years Considered
Figure 5. Global PEGylated Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by PEGylated Drugs Revenue in 2023
Figure 7. PEGylated Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Macromolecular Drugs Picture
Figure 9. Small Molecular Drugs Picture
Figure 10. Nanoparticles Picture
Figure 11. Global PEGylated Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global PEGylated Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of Cancer
Figure 14. Product Picture of Hepatitis C
Figure 15. Product Picture of Leukemia
Figure 16. Product Picture of Severe Combined Immunodeficiency Disease
Figure 17. Product Picture of Rheumatoid Arthritis
Figure 18. Product Picture of Crohn Disease
Figure 19. Product Picture of Others
Figure 20. Global PEGylated Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global PEGylated Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 22. North America PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 23. North America PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 24. Europe PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 26. Asia Pacific PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia Pacific PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 28. South America PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. South America PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 32. Key Countries/Regions PEGylated Drugs Sales Value (%), (2019-2030)
Figure 33. United States PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 34. United States PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 35. United States PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 36. Europe PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 37. Europe PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 38. Europe PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 39. China PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 40. China PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 41. China PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 42. Japan PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 43. Japan PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 44. Japan PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 45. South Korea PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 46. South Korea PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 47. South Korea PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 48. Southeast Asia PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 49. Southeast Asia PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 50. Southeast Asia PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 51. India PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 52. India PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 53. India PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 54. PEGylated Drugs Industrial Chain
Figure 55. PEGylated Drugs Manufacturing Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Table 1. PEGylated Drugs Market Trends
Table 2. PEGylated Drugs Market Drivers & Opportunity
Table 3. PEGylated Drugs Market Challenges
Table 4. PEGylated Drugs Market Restraints
Table 5. Global PEGylated Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global PEGylated Drugs Revenue Market Share by Company (2019-2024)
Table 7. Key Companies PEGylated Drugs Manufacturing Base Distribution and Headquarters
Table 8. Key Companies PEGylated Drugs Product Type
Table 9. Key Companies Time to Begin Mass Production of PEGylated Drugs
Table 10. Global PEGylated Drugs Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PEGylated Drugs as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global PEGylated Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global PEGylated Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global PEGylated Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global PEGylated Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global PEGylated Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global PEGylated Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global PEGylated Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global PEGylated Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global PEGylated Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global PEGylated Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global PEGylated Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global PEGylated Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global PEGylated Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global PEGylated Drugs Sales Value by Region (2019-2024) & (%)
Table 27. Global PEGylated Drugs Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions PEGylated Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions PEGylated Drugs Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions PEGylated Drugs Sales Value, (2025-2030) & (US$ Million)
Table 31. AstraZeneca Basic Information List
Table 32. AstraZeneca Description and Business Overview
Table 33. AstraZeneca PEGylated Drugs Products, Services and Solutions
Table 34. Revenue (US$ Million) in PEGylated Drugs Business of AstraZeneca (2019-2024)
Table 35. AstraZeneca Recent Developments
Table 36. Bayer Healthcare Basic Information List
Table 37. Bayer Healthcare Description and Business Overview
Table 38. Bayer Healthcare PEGylated Drugs Products, Services and Solutions
Table 39. Revenue (US$ Million) in PEGylated Drugs Business of Bayer Healthcare (2019-2024)
Table 40. Bayer Healthcare Recent Developments
Table 41. Biogen Basic Information List
Table 42. Biogen Description and Business Overview
Table 43. Biogen PEGylated Drugs Products, Services and Solutions
Table 44. Revenue (US$ Million) in PEGylated Drugs Business of Biogen (2019-2024)
Table 45. Biogen Recent Developments
Table 46. BioMarin Pharmaceutical Inc Basic Information List
Table 47. BioMarin Pharmaceutical Inc Description and Business Overview
Table 48. BioMarin Pharmaceutical Inc PEGylated Drugs Products, Services and Solutions
Table 49. Revenue (US$ Million) in PEGylated Drugs Business of BioMarin Pharmaceutical Inc (2019-2024)
Table 50. BioMarin Pharmaceutical Inc Recent Developments
Table 51. Coherus BioSciences Basic Information List
Table 52. Coherus BioSciences Description and Business Overview
Table 53. Coherus BioSciences PEGylated Drugs Products, Services and Solutions
Table 54. Revenue (US$ Million) in PEGylated Drugs Business of Coherus BioSciences (2019-2024)
Table 55. Coherus BioSciences Recent Developments
Table 56. Enzon Basic Information List
Table 57. Enzon Description and Business Overview
Table 58. Enzon PEGylated Drugs Products, Services and Solutions
Table 59. Revenue (US$ Million) in PEGylated Drugs Business of Enzon (2019-2024)
Table 60. Enzon Recent Developments
Table 61. Horizon Therapeutics Basic Information List
Table 62. Horizon Therapeutics Description and Business Overview
Table 63. Horizon Therapeutics PEGylated Drugs Products, Services and Solutions
Table 64. Revenue (US$ Million) in PEGylated Drugs Business of Horizon Therapeutics (2019-2024)
Table 65. Horizon Therapeutics Recent Developments
Table 66. Leadiant Biosciences, Inc. Basic Information List
Table 67. Leadiant Biosciences, Inc. Description and Business Overview
Table 68. Leadiant Biosciences, Inc. PEGylated Drugs Products, Services and Solutions
Table 69. Revenue (US$ Million) in PEGylated Drugs Business of Leadiant Biosciences, Inc. (2019-2024)
Table 70. Leadiant Biosciences, Inc. Recent Developments
Table 71. Merck Basic Information List
Table 72. Merck Description and Business Overview
Table 73. Merck PEGylated Drugs Products, Services and Solutions
Table 74. Revenue (US$ Million) in PEGylated Drugs Business of Merck (2019-2024)
Table 75. Merck Recent Developments
Table 76. Mylan Basic Information List
Table 77. Mylan Description and Business Overview
Table 78. Mylan PEGylated Drugs Products, Services and Solutions
Table 79. Revenue (US$ Million) in PEGylated Drugs Business of Mylan (2019-2024)
Table 80. Mylan Recent Developments
Table 81. Novo Nordisk Basic Information List
Table 82. Novo Nordisk Description and Business Overview
Table 83. Novo Nordisk PEGylated Drugs Products, Services and Solutions
Table 84. Revenue (US$ Million) in PEGylated Drugs Business of Novo Nordisk (2019-2024)
Table 85. Novo Nordisk Recent Developments
Table 86. Pfizer Basic Information List
Table 87. Pfizer Description and Business Overview
Table 88. Pfizer PEGylated Drugs Products, Services and Solutions
Table 89. Revenue (US$ Million) in PEGylated Drugs Business of Pfizer (2019-2024)
Table 90. Pfizer Recent Developments
Table 91. Roche Basic Information List
Table 92. Roche Description and Business Overview
Table 93. Roche PEGylated Drugs Products, Services and Solutions
Table 94. Revenue (US$ Million) in PEGylated Drugs Business of Roche (2019-2024)
Table 95. Roche Recent Developments
Table 96. Sandoz Basic Information List
Table 97. Sandoz Description and Business Overview
Table 98. Sandoz PEGylated Drugs Products, Services and Solutions
Table 99. Revenue (US$ Million) in PEGylated Drugs Business of Sandoz (2019-2024)
Table 100. Sandoz Recent Developments
Table 101. Servier Pharmaceuticals LLC Basic Information List
Table 102. Servier Pharmaceuticals LLC Description and Business Overview
Table 103. Servier Pharmaceuticals LLC PEGylated Drugs Products, Services and Solutions
Table 104. Revenue (US$ Million) in PEGylated Drugs Business of Servier Pharmaceuticals LLC (2019-2024)
Table 105. Servier Pharmaceuticals LLC Recent Developments
Table 106. Takeda Pharmaceutical Company Limited Basic Information List
Table 107. Takeda Pharmaceutical Company Limited Description and Business Overview
Table 108. Takeda Pharmaceutical Company Limited PEGylated Drugs Products, Services and Solutions
Table 109. Revenue (US$ Million) in PEGylated Drugs Business of Takeda Pharmaceutical Company Limited (2019-2024)
Table 110. Takeda Pharmaceutical Company Limited Recent Developments
Table 111. Key Raw Materials Lists
Table 112. Raw Materials Key Suppliers Lists
Table 113. PEGylated Drugs Downstream Customers
Table 114. PEGylated Drugs Distributors List
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
Table 118. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. PEGylated Drugs Product Picture
Figure 2. Global PEGylated Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. PEGylated Drugs Report Years Considered
Figure 5. Global PEGylated Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by PEGylated Drugs Revenue in 2023
Figure 7. PEGylated Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Macromolecular Drugs Picture
Figure 9. Small Molecular Drugs Picture
Figure 10. Nanoparticles Picture
Figure 11. Global PEGylated Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global PEGylated Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of Cancer
Figure 14. Product Picture of Hepatitis C
Figure 15. Product Picture of Leukemia
Figure 16. Product Picture of Severe Combined Immunodeficiency Disease
Figure 17. Product Picture of Rheumatoid Arthritis
Figure 18. Product Picture of Crohn Disease
Figure 19. Product Picture of Others
Figure 20. Global PEGylated Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global PEGylated Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 22. North America PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 23. North America PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 24. Europe PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 26. Asia Pacific PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia Pacific PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 28. South America PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. South America PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa PEGylated Drugs Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa PEGylated Drugs Sales Value by Country (%), 2023 VS 2030
Figure 32. Key Countries/Regions PEGylated Drugs Sales Value (%), (2019-2030)
Figure 33. United States PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 34. United States PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 35. United States PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 36. Europe PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 37. Europe PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 38. Europe PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 39. China PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 40. China PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 41. China PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 42. Japan PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 43. Japan PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 44. Japan PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 45. South Korea PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 46. South Korea PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 47. South Korea PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 48. Southeast Asia PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 49. Southeast Asia PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 50. Southeast Asia PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 51. India PEGylated Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 52. India PEGylated Drugs Sales Value by Type (%), 2023 VS 2030
Figure 53. India PEGylated Drugs Sales Value by Application (%), 2023 VS 2030
Figure 54. PEGylated Drugs Industrial Chain
Figure 55. PEGylated Drugs Manufacturing Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232